Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism

Journal of Clinical Microbiology

Volumn 51, Issue 5, 2013, Pages 1517-1527

  Weber, Jan ^a   Vazquez, Ana C ^b   Winner, Dane ^b   Gibson, Richard M ^c   Rhea, Ariel M ^b   Rose, Justine D ^b   Wylie, Doug ^b   Henry, Kenneth ^c   Wright, Alison ^b   King, Kevin ^b   Archer, John ^d   Poveda, Eva ^e   Soriano, Vicente ^e   Robertson, David L ^d   Olivo, Paul D ^b   Arts, Eric J ^c   Quiñones Mateu, Miguel E ^f,g  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b Quidel Corporation   (United States)

^c Division of Infectious Diseasesc Department of Pathology   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MARAVIROC; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CXCR4 PROTEIN, HUMAN; CYCLOHEXANE DERIVATIVE; SACCHAROMYCES CEREVISIAE PROTEIN; TRIAZOLE DERIVATIVE; URA3 PROTEIN, S CEREVISIAE; VIRUS ENVELOPE PROTEIN; VIRUS RECEPTOR; VIRUS RNA;

ALGORITHM; ANALYTICAL EQUIPMENT; ARTICLE; ASSAY; BETA GALACTOSIDASE GENE; BIOINFORMATICS; CELL TO CELL FUSION ASSAY; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENVELOPE GENE; FALSE POSITIVE RESULT; FUNGAL GENE; GENE REPLICATION; GENE SEQUENCE; GENE VECTOR; GENETIC VARIABILITY; GENOTYPE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERMETHOD COMPARISON; MOLECULAR CLONING; NONHUMAN; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; URA3 GENE; VIRAL TROPISM; VIRUS GENOME; VIRUS LOAD; ANTAGONISTS AND INHIBITORS; CELL FUSION; CELL LINE; EVALUATION STUDY; GENETICS; HEK293 CELL LINE; HIV INFECTIONS; METABOLISM; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; CELL FUSION; CELL LINE; CYCLOHEXANES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOME, VIRAL; GENOTYPE; HEK293 CELLS; HIV INFECTIONS; HIV-1; HUMANS; PILOT PROJECTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; RNA, VIRAL; SACCHAROMYCES CEREVISIAE PROTEINS; SENSITIVITY AND SPECIFICITY; TRIAZOLES; VIRAL TROPISM;

EID: 84876750679     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00092-13     Document Type: Article

References (69)

1. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763-767.
2. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, Gluckman JC, Montagnier L. 1984. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312:767-768.
3. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. 1996. HIV-1 entry into CD4-cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
4. Feng Y, Broder CC, Kennedy PE, Berger EA. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
5. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
6. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA. 1998. A new classification for HIV-1. Nature 391:240.
7. Frange P, Chaix ML, Raymond S, Galimand J, Deveau C, Meyer L, Goujard C, Rouzioux C, Izopet J. 2010. Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection. J. Clin. Microbiol. 48:3487-3491.
8. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. 1993. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179-1181.
9. Bomsel M, David V. 2002. Mucosal gatekeepers: selecting HIV viruses for early infection. Nat. Med. 8:114-116.
10. Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG. 2005. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis. 191:866-872.
11. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. 1997. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621-628.
12. Poveda E, Briz V, Quinones-Mateu M, Soriano V. 2006. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 20:1359-1367.
13. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
14. Rose JD, Rhea AM, Weber J, Quinones-Mateu ME. 2009. Current tests to evaluate HIV-1 coreceptor tropism. Curr. Opin. HIV AIDS 4:136-142.
15. Weber J, Piontkivska H, Quinones-Mateu ME. 2006. HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Rev. 8:60-77.
16. Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heveker N, Alizon M, Scarlatti G, Clavel F, Mammano F. 2001. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J. Virol. 75:251-259.
17. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51:566-575.
18. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Encinas S, Bruel P, Sandres-Saune K, Marchou B, Massip P, Izopet J. 2010. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J. Clin. Virol. 47:126-130.
19. Holland AU, Munk C, Lucero GR, Nguyen LD, Landau NR. 2004. Alpha-complementation assay for HIV envelope glycoprotein-mediated fusion. Virology 319:343-352.
20. Grund S, Klein A, Adams O. 2010. Expression plasmids are only useful for the investigation of co-receptor tropism and fusion capacity of short HIV-1 envelope domains. J. Virol. Methods 166:106-109.
21. Obermeier M, Symons J, Wensing AM. 2012. HIV population genotypic tropism testing and its clinical significance. Curr. Opin. HIV AIDS 7:470-477.
22. Swenson LC, Moores A, Low AJ, Thielen A, Dong W, Woods C, Jensen MA, Wynhoven B, Chan D, Glascock C, Harrigan PR. 2010. Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA. J. Acquir. Immune Defic. Syndr. 54:506-510.
23. Swenson LC, Daumer M, Paredes R. 2012. Next-generation sequencing to assess HIV tropism. Curr. Opin. HIV AIDS 7:478-485.
24. Archer J, Braverman MS, Taillon BE, Desany B, James I, Harrigan PR, Lewis M, Robertson DL. 2009. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultradeep pyrosequencing. AIDS 23:1209-1218.
25. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, Domingues FS, Buch J, Daumer M, Kaiser R, Lengauer T, Harrigan PR. 2007. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir. Ther. 12:1097-1106.
26. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. 2003. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol. 77:13376-13388.
27. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. 2007. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res. Hum. Retroviruses 23:415-426.
28. Rosen O, Sharon M, Quadt-Akabayov SR, Anglister J. 2006. Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Proc. Natl. Acad. Sci. U. S. A. 103:13950-13955.
29. Lin NH, Kuritzkes DR. 2009. Tropism testing in the clinical management of HIV-1 infection. Curr. Opin. HIV AIDS 4:481-487.
30. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478-7487.
31. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
32. Poveda E, Seclen E, Gonzalez MM, Garcia F, Chueca N, Aguilera A, Rodriguez JJ, Gonzalez-Lahoz J, Soriano V. 2009. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J. Antimicrob. Chemother. 63:1006-1010.
33. Moreno S, Clotet B, Sarria C, Ortega E, Leal M, Rodriguez-Arrondo F, Sanchez-de la Rosa R, Allegro Study Group. 2009. Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain. HIV Clin. Trials 10:394-402.
34. Dudley DM, Gao Y, Nelson KN, Henry KR, Nankya I, Gibson RM, Arts EJ. 2009. A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques 46:458-467.
35. Weber J, Vazquez AC, Winner D, Rose JD, Wylie D, Rhea AM, Henry K, Pappas J, Wright A, Mohamed N, Gibson R, Rodriguez B, Soriano V, King K, Arts EJ, Olivo PD, Quinones-Mateu ME. 2011. Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3=Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy. Antimicrob. Agents Chemother. 55:3729-3742.
36. Archer J, Weber J, Henry K, Winner D, Gibson R, Lee L, Paxinos E, Arts EJ, Robertson DL, Mimms L, Quinones-Mateu ME. 2012. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One 7:e49602. doi:10.1371/journal.pone.0049602.
37. Archer J, Baillie G, Watson SJ, Kellam P, Rambaut A, Robertson DL. 2012. Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminatr II. BMC Bioinformatics 13:47.
38. Archer J, Rambaut A, Taillon BE, Harrigan PR, Lewis M, Robertson DL. 2010. The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time-an ultra-deep approach. PLoS Comput. Biol. 6:e1001022. doi:10.1371/journal.pcbi.1001022.
39. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Jensen MA, Thielen A, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2011. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J. Infect. Dis. 203:237-245.
40. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, Thielen A, Jensen MA, Knapp DJ, Chapman D, Portsmouth S, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2011. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin. Infect. Dis. 53:732-742.
41. Swenson LC, McGovern RA, Dong W, Mo T, Lee GQ, Thielen A, et al. 2009. Optimization of clinically relevant cutoffs for determining HIV coreceptor use by population and deep sequencing methods. Infectious Diseases Society of America 47th Annual Meeting Philadelphia, PA, 29 October to 1 November 2009.
42. Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM. 2009. An enhanced-sensitivity Trofile™ HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J. Viral Entry 3:94-102.
43. Paar C, Geit M, Stekel H, Berg J. 2011. Genotypic prediction of human immunodeficiency virus type 1 tropism by use of plasma and peripheral blood mononuclear cells in the routine clinical laboratory. J. Clin. Microbiol. 49:2697-2699.
44. Moore JP, Kitchen SG, Pugach P, Zack JA. 2004. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 20:111-126.
45. Soulie C, Calvez V, Marcelin AG. 2012. Coreceptor usage in different reservoirs. Curr. Opin. HIV AIDS 7:450-455.
46. Verhofstede C, Nijhuis M, Vandekerckhove L. 2012. Correlation of coreceptor usage and disease progression. Curr. Opin. HIV AIDS 7:432-439.
47. Raymond S, Delobel P, Izopet J. 2012. Phenotyping methods for determining HIV tropism and applications in clinical settings. Curr. Opin. HIV AIDS 7:463-469.
48. Japour AJ, Fiscus SA, Arduino JM, Mayers DL, Reichelderfer PS, Kuritzkes DR. 1994. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J. Clin. Microbiol. 32:2291-2294.
49. Princen K, Hatse S, Vermeire K, De Clercq E, Schols D. 2004. Establishment of a novel CCR5 and CXCR4 expressing CD4-cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology 1:2.
50. Kajiwara K, Kodama E, Matsuoka M. 2006. A novel colorimetric assay for CXCR4 and CCR5 tropic human immunodeficiency viruses. Antiviral Chem. Chemother. 17:215-223.
51. Trkola A, Ketas T, Kewalramani VN, Endorf F, Binley JM, Katinger H, Robinson J, Littman DR, Moore JP. 1998. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J. Virol. 72:1876-1885.
52. Meyerhans A, Cheynler R, Albert J, Seth M, Kwok S, Sninsky J, Morfeldt-Manson L, Asjî B, Wain-Hobson S. 1989. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 58:901-910.
53. Gonzalez-Serna A, Leal M, Genebat M, Abad MA, Garcia-Perganeda A, Ferrando-Martinez S, Ruiz-Mateos E. 2010. TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches. J. Clin. Microbiol. 48:4453-4458.
54. Lineberger JE, Danzeisen R, Hazuda DJ, Simon AJ, Miller MD. 2002. Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion. J. Virol. 76:3522-3533.
55. Nussbaum O, Broder CC, Berger EA. 1994. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J. Virol. 68:5411-5422.
56. Ji C, Zhang J, Cammack N, Sankuratri S. 2006. Development of a novel dual CCR5-dependent and CXCR4-dependent cell-cell fusion assay system with inducible gp160 expression. J. Biomol. Screen. 11:65-74.
57. Saliou A, Delobel P, Dubois M, Nicot F, Raymond S, Calvez V, Masquelier B, Izopet J. 2011. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob. Agents Chemother. 55:2831-2836.
58. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429-1441.
59. Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD. 2009. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J. Infect. Dis. 200:1724-1728.
60. Poveda E, Alcami J, Paredes R, Cordoba J, Gutierrez F, Llibre JM, Delgado R, Pulido F, Iribarren JA, Garcia Deltoro M, Hernandez Quero J, Moreno S, Garcia F. 2010. Genotypic determination of HIV tropism-clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Rev. 12:135-148.
61. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:4909-4920.
62. Marier JF, Trinh M, Pheng LH, Palleja SM, Martin DE. 2011. Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients. Antimicrob. Agents Chemother. 55:2768-2774.
63. Gonzalez N, Perez-Olmeda M, Mateos E, Cascajero A, Alvarez A, Spijkers S, Garcia-Perez J, Sanchez-Palomino S, Ruiz-Mateos E, Leal M, Alcami J. 2010. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J. Antimicrob. Chemother. 65:2493-2501.
64. Skrabal K, Low AJ, Dong W, Sing T, Cheung PK, Mammano F, Harrigan PR. 2007. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J. Clin. Microbiol. 45:279-284.
65. de Mendoza C, Van Baelen K, Poveda E, Rondelez E, Zahonero N, Stuyver L, Garrido C, Villacian J, Soriano V. 2008. Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. J. Acquir. Immune. Defic. Syndr. 48:241-244.
66. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres-Saune K, Cuzin L, Marchou B, Massip P, Izopet J. 2008. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22:F11-F16.
67. Trabaud MA, Icard V, Scholtes C, Perpoint T, Koffi J, Cotte L, Makhloufi D, Tardy JC, Andre P. 2012. Discordance in HIV-1 coreceptor use prediction by different genotypic algorithms and phenotype assay: intermediate profile in relation to concordant predictions. J. Med. Virol. 84:402-413.
68. Recordon-Pinson P, Soulie C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Mace M, Ferre V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B. 2010. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob. Agents Chemother. 54:3335-3340.
69. Seclen E, Soriano V, Gonzalez MM, Gomez S, Thielen A, Poveda E. 2011. High concordance between the position-specific scoring matrix and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreement. J. Clin. Microbiol. 49:3380-3382.